GLP-1semaglutidepregnancyglp-1 receptor agonistssglt2 inhibitorscanada

Manitoba data show GLP-1 dispensing in pregnancy rising eightfold since 2021

GLP-1 receptor agonist dispensing climbed from 0.44 to 3.72 per 1000 pregnancies between 2021 and 2023 across 171,103 pregnancies studied.

By Maren Holt · Senior Reporter, GLP-1

Oct 5 20:00 ETSource: Obesity research & clinical practice

The wire

01Retrospective analysis of Manitoba administrative health data covering 171,103 pregnancies from January 2015 to March 2023 found GLP-1 RA dispensing rose from 0.44 per 1000 in 2021 to 3.72 in 2023.
02Prescribers and pharmacists counselling patients of childbearing age now have population-level evidence that incretin exposure around pregnancy, while uncommon, is climbing quickly.
03Absolute rates remain low and the data are dispensing records only, with no information on timing within pregnancy, adherence or fetal outcomes.

From the source

Temporal trends in GLP-1 receptor agonist and SGLT2 inhibitor dispensing during pregnancy in Manitoba, Canada, 2015-2023
Obesity research & clinical practice · 2026 Oct 6 · Peymani P, Aboulatta L, Khan MW et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42838854/